Genomic Vision Attended the 20th Edition of the European Drug Discovery Innovation Programme in Barcelona

• The event highlighted the rising importance of artificial intelligence (AI) and machine learning (ML) in drug discovery.
• Genomic Vision actively engaged in networking, fostering new customers interested in GV technology and its applications in general.
• Genomic Vision's Replication Combing Assay (RCA) aligns with evolving biotech trends, reaffirming its commitment to advancing drug discovery and pharmaceutical efficiency.

BAGNEUX, France--(BUSINESS WIRE)--Regulatory News:

Genomic Vision (FR0011799907 – GV, – the “Company”), a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, was delighted to take part in the 20^th Edition of the European Drug Discovery Innovation Programme held in Barcelona on September 12^th and 13^th.

This prominent event provided an invaluable opportunity for Genomic Vision's teams to reinforce a comprehensive understanding of customer demands in the quickly evolving pharmaceutical environment. It became evident that there is a very significant interest in artificial intelligence (AI) and machine learning (ML) within the drug discovery pipeline, highlighting their growing impact and importance in the industry.

During this event, Genomic Vision engaged in meaningful interactions, fostering new interested customer, and participating in professional discussions. The company had the privilege of attending several highly informative conferences on the subject of AI and ML in drug discovery. These sessions were fully in line with Genomic Vision's commitment to staying at the front of the technology advancements and positioning itself as a key player in this dynamic industry.

Indeed, Genomic Vision's innovative technology and its diverse range of applications are clearly associated with the evolving trends in biotechnology and the future of drug research. The company's participation in this event reaffirmed its dedication to facilitating advancements in drug discovery and enhancing the efficiency of pharmaceutical industry.

Yann BENUREAU, Senior Scientist at Genomic Vision, said: “This event gave us the opportunity to showcase our technology and observe the keen interest it has generated in the scientific community to shape the future of drug discovery. Our commitment to continuous adaptation and innovation remains unwavering as we strive to meet the evolving needs of our customers and the pharmaceutical industry as a whole.”

ABOUT THE EUROPEAN DRUG DISCOVERY INNOVATION PROGRAMME

The European Drug Discovery Innovation Programme is a prominent event in the field of pharmaceutical research in Europe. It brings together experts, researchers, and industry professionals to discuss the latest advancements, innovations and trends in drug discovery. This event provides a platform for knowledge exchange, professional networking, and thorough discussions on topics such as artificial intelligence, machine learning, and other technological advancements crucial to the future of pharmaceutical research. It represents a significant opportunity for companies and researchers to stay at the forefront of innovation and contribute to the ongoing improvement of medical treatments.

ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology company that develops products and services for the highly accurate characterization of genome modifications. We deliver high-quality integrated genomic analysis solutions to improve quality control and bioproduction standards of advanced gene therapies at scale. Based on molecular combing technology and artificial intelligence, The Company provides robust quantitative measurements needed for high confidence characterization of transformed cell lines and prediction of cell line performance, in particular in the context of the biomanufacturing processes of cell and gene therapies. Genomic Vision’s molecular combing technology has further applications in drug development of agents targeting DNA replication and damage response mechanisms, visualizing DNA replication kinetics and telomere length maintenance. Genomic Vision, based near Paris in Bagneux, is a public company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).

For further information, please visit www.genomicvision.com

Member of the CAC^® Mid & Small and CAC^® All-Tradable indices

FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the universal registration document filed with the AMF on April 28, 2023 under number D.23-0383, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

Genomic Vision has set up a financing line in the form of convertible notes with warrants (OCABSA) with its Financing partner.
The shares resulting from the conversion or exercise of the aforementioned securities will, in general, be sold on the market, which could create downward pressure on the share price as well as a dilution.
Shareholders could therefore suffer a loss of their invested capital due to a significant decrease in the value of the company's shares. The company has carried out several dilutive financing operations, and investors are advised to be very careful before making a decision to invest in the company's securities.

Genomic Vision
Aaron Bensimon
Chairman of the Management Board
Tel.: +33 1 49 08 07 51
investisseurs@genomicvision.com

Ulysse Communication
Media Relations
Bruno Arabian
Tel.: +33 1 42 68 29 70
barabian@ulysse-communication.com

Consilium Strategic Communications
International Investor Relations
& Strategic Communications
Tel.: +44 (0) 20 3709 5700
GenomicVision@consilium-comms.com

NewCap
France Investor Relations
& Strategic Communications
Tel.: +33 1 44 71 94 94
gv@newcap.eu